The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors (Q38126109)

29 August 2017

The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors (English)

1 reference

29 August 2017

S Cangoz

1

1 reference

29 August 2017

Y-Y Chang

2

1 reference

29 August 2017

S J Chempakaseril

3

1 reference

29 August 2017

R C Guduru

4

1 reference

29 August 2017

L M Huynh

5

1 reference

29 August 2017

J S John

6

1 reference

29 August 2017

S T John

7

1 reference

29 August 2017

M E Joseph

8

1 reference

29 August 2017

R Judge

9

1 reference

29 August 2017

R Kimmey

10

1 reference

29 August 2017

K Kudratov

11

1 reference

29 August 2017

P J Lee

12

1 reference

29 August 2017

I C Madhani

13

1 reference

29 August 2017

P J Shim

14

1 reference

29 August 2017

S Singh

15

1 reference

29 August 2017

S Singh

16

1 reference

29 August 2017

C Ruchalski

17

1 reference

29 August 2017

R B Raffa

18

1 reference

29 August 2017

12 June 2013

1 reference

Journal of Clinical Pharmacy and Therapeutics

29 August 2017

1 reference

29 August 2017

38

1 reference

29 August 2017

350-359

1 reference

29 August 2017

5

1 reference

Standards of medical care in diabetes--2012

29 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

A clinical trial to maintain glycemic control in youth with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Diabetes mellitus: new drugs for a new epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Autoantibodies in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Antigenicity of insulin: diabetes induced by specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

The stunned beta cell: a brief history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Molecular mechanism of insulin resistance in obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Minireview: Epigenetics of obesity and diabetes in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Community-based lifestyle interventions to prevent type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

The SLC2 family of facilitated hexose and polyol transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

The sodium/glucose cotransport family SLC5

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

SGLT inhibitors as new therapeutic tools in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Phloridzin: biosynthesis, distribution and physiological relevance in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Dapagliflozin: more than just another oral glucose-lowering agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Dapagliflozin, an SGLT2 inhibitor, for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Dapagliflozin: where does it fit in the treatment of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

SGLT gene expression in primary lung cancers and their metastatic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Regulatory mechanisms of intracellular distribution of Na+-dependent glucose transporter and the role in recovery from cellular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Survival of cancer cells is maintained by EGFR independent of its kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

Genotyping analysis of Helicobacter pylori using multiple-locus variable-number tandem-repeats analysis in five regions of China and Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12077

21 January 2018

Identifiers

DOI

10.1111/JCPT.12077

1 reference

29 August 2017

1 reference